Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etazolate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.67 |
| ▸ | PDE5A | O76074 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etazolate SCHEMBL29824913 | 1.00 | MEN1 (0.98) | MEN1MAPTHPGDBLMPMP22 | |
| Etazolate SCHEMBL16703320 | 1.00 | MEN1 (0.98) | MEN1MAPTHPGDBLMPMP22 | |
| Etazolate SCHEMBL123105 | 0.99 | MEN1 (1.00) | MEN1MAPTHPGDBLMPMP22 | |
| Etazolate SCHEMBL1004450 | 0.98 | MEN1 (0.94) | MEN1MAPTHPGDBLMPMP22 | |
| Etazolate SCHEMBL16702579 | 0.98 | MEN1 (0.94) | MEN1MAPTHPGDBLMPMP22 | |
| SCHEMBL2459284 | 0.89 | MEN1 (0.79) | MEN1MAPTHPGDBLMPMP22 | |
| SCHEMBL2459785 | 0.89 | MEN1 (0.79) | MEN1MAPTHPGDBLMPMP22 | |
| SCHEMBL2455499 | 0.88 | MAPT (0.77) | MEN1MAPTHPGDBLMPMP22 | |
| SCHEMBL17017274 | 0.87 | MEN1 (0.76) | MEN1MAPTHPGDBLMPMP22 | |
| SCHEMBL2463203 | 0.86 | MEN1 (0.74) | MEN1MAPTHPGDBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2109 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2024-09-26 | — | — | US | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| EP-4282413-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-11-29 | — | — | EP | claimed |
| CN-116963773-A | Compositions and methods for treating tumors | 浙江养生堂天然药物研究所有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230338345-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-10-26 | — | — | US | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| CN-109563089-B | Compounds that promote normal processing of APP | 巴克老年研究所 | 2023-06-16 | — | — | CN | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4140480-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-03-01 | — | — | EP | claimed |
| CN-115397411-A | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| EP-1012188-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN, Wolf-Georg, Prof. Dr. (DE) | 2000-06-28 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1999014239-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN WOLF GEORG (DE) | 1999-03-25 | — | — | WO | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| US-4980379-A | ENHANCING EFFICIENCY BY REDUCING ADENOSINE LEVELS | THE UNIVERSITY OF VIRGINIA (US) | 1990-12-25 | — | — | US | claimed |
| US-4904472-A | Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation | THE UNIVERSITY OF VIRGINIA ALUMNI PATENT FOUNDATION (US) | 1990-02-27 | — | — | US | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-4147789-A | ANTIPARKINSON AGENTS | SANDOZ LTD. (CH) | 1979-04-03 | — | — | US | claimed |